c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial
- DOI
- 10.1186/s12916-022-02270-y
- Published
- 2022-02-11
- Container
- BMC Medicine
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s12916-022-02270-y,
title = {c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial},
author = {Robert D. Morgan and Cristina Ferreras and Isabel Peset and Egle Avizienyte and Andrew G. Renehan and Richard J. Edmondson and Alexander D. Murphy and Shibani Nicum and Thomas Van Brussel and Andrew R. Clamp and Diether Lambrechts and Cong Zhou and Gordon C. Jayson},
year = {2022},
journal = {BMC Medicine},
doi = {10.1186/s12916-022-02270-y},
url = {https://doi.org/10.1186/s12916-022-02270-y}
}RIS
TY - JOUR TI - c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial AU - Robert D. Morgan AU - Cristina Ferreras AU - Isabel Peset AU - Egle Avizienyte AU - Andrew G. Renehan AU - Richard J. Edmondson AU - Alexander D. Murphy AU - Shibani Nicum AU - Thomas Van Brussel AU - Andrew R. Clamp AU - Diether Lambrechts AU - Cong Zhou AU - Gordon C. Jayson PY - 2022 JO - BMC Medicine DO - 10.1186/s12916-022-02270-y UR - https://doi.org/10.1186/s12916-022-02270-y ER -
APA
Morgan, R. D., Ferreras, C., Peset, I., Avizienyte, E., Renehan, A. G., Edmondson, R. J., Murphy, A. D., Nicum, S., Brussel, T. V., Clamp, A. R., Lambrechts, D., Zhou, C., & Jayson, G. C. (2022). c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial. BMC Medicine. https://doi.org/10.1186/s12916-022-02270-y
Source records
- crossref · retrieved 2026-09-26T02:17:21.719Z